December 6, 2023 — Founding Partner Jennifer Wu moderated an in-house counsel panel on current issues in Biologics Price Competition and Innovation (BPCIA) litigation on December 1, 2023 as part of the Practicing Law Institute’s Developments in Pharmaceutical and Biotech Patent Law 2023 program. The panelists Ryan Daniel (Fresenius), Petra Scamborova (Regeneron), Jill Schmidt (Genentech), and Josephine Liu (formerly Sandoz) discussed whether the BPCIA framework promotes innovation, differences in ANDA and BPCIA litigation, open issues in BPCIA litigation as well as ones that have been resolved, the impact of Amgen v Sanofi and GSK v. Teva, and in-house considerations in managing BPCIA litigation.

Jennifer has done extensive work in cutting-edge biologics cases. She was recently recognized by Benchmark Litigation as a “Future Star” and has been named to Lawdragon’s 500 Leading Litigators in America list for 2023 and 2024.